Zobrazeno 1 - 10 of 20 pro vyhledávání: '"Aix, SP"'
2
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Autor: Rosell, R, Dafni, U, Felip, E, Curioni-Fontecedro, A, Gautschi, O, Peters, S, Massuti, B, Palmero, R, Aix, SP, Carcereny, E, Fruh, M, Pless, M, Popat, S, Kotsakis, A, Cuffe, S, Bidoli, P, Favaretto, A, Froesch, P, Reguart, N, Puente, J, Coate, L, Barlesi, F, Rauch, D, Thomas, M, Camps, C, Gomez-Codina, J, Majem, M, Porta, R, Shah, R, Hanrahan, E, Kammler, R, Ruepp, B, Rabaglio, M, Kassapian, M, Karachaliou, N, Tam, R, Shames, DS, Molina-Vila, MA, Stahel, RA, BELIEF collaborative group
Publikováno v: LANCET RESPIRATORY MEDICINE
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
BACKGROUND: The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1dce3a39f83b6ce9506a1fd9ad0d3fa7
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6203
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
Autor: Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF, EMPHASIS-lung Collaborative Group
Publikováno v: JOURNAL OF THORACIC ONCOLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Journal of Thoracic Oncology, 12(4), 752-762. International Association for the Study of Lung Cancer
Peters, S, Stahel, R A, Dafni, U, Ponce Aix, S, Massutí, B, Gautschi, O, Coate, L, López Martín, A, van Heemst, R, Berghmans, T, Meldgaard, P, Cobo Dols, M, Garde Noguera, J, Curioni-Fontecedro, A, Rauch, D, Mark, M T, Cuffe, S, Biesma, B, van Henten, A M J, Juan Vidal, Ó, Palmero Sanchez, R, Villa Guzmán, J C, Collado Martin, R, Peralta, S, Insa, A, Summers, Y, Láng, I, Horgan, A, Ciardiello, F, de Hosson, S, Pieterman, R, Groen, H J M, van den Berg, P M, Zielinski, C C, Chittazhathu Kurian Kuruvilla, Y, Gasca-Ruchti, A, Kassapian, M, Novello, S, Torri, V, Tsourti, Z, Gregorc, V, Smit, E F & EMPHASIS-lung Collaborative Group 2017, ' Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial ', Journal of Thoracic Oncology, vol. 12, no. 4, pp. 752-762 . https://doi.org/10.1016/j.jtho.2016.12.017
Peters, S, Stahel, R A, Dafni, U, Ponce Aix, S, Massutí, B, Gautschi, O, Coate, L, López Martín, A, van Heemst, R, Berghmans, T, Meldgaard, P, Cobo Dols, M, Garde Noguera, J, Curioni-Fontecedro, A, Rauch, D, Mark, M T, Cuffe, S, Biesma, B, van Henten, A M J, Juan Vidal, Ó, Palmero Sanchez, R, Villa Guzmán, J C, Collado Martin, R, Peralta, S, Insa, A, Summers, Y, Láng, I, Horgan, A, Ciardiello, F, de Hosson, S, Pieterman, R, Groen, H J M, van den Berg, P M, Zielinski, C C, Chittazhathu Kurian Kuruvilla, Y, Gasca-Ruchti, A, Kassapian, M, Novello, S, Torri, V, Tsourti, Z, Gregorc, V, Smit, E F & EMPHASIS-lung Collaborative Group 2017, ' Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial ', Journal of Thoracic Oncology, vol. 12, no. 4, pp. 752-762 . https://doi.org/10.1016/j.jtho.2016.12.017
Journal of Thoracic Oncology, 12(4), 752-762. ELSEVIER SCIENCE INC
Introduction: Docetaxel and erlotinib are registered second line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second line therapy of NSCLC, classifying patients as either VeriStrat good o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee1d367d8bc33b24edc27d000909d5bd
https://pubmed.ncbi.nlm.nih.gov/28343541
Zobrazit plný text záznamu
6
Akademický článek
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR -Mutant Non-Small-Cell Lung Cancer.
Autor: Remon J; Paris-Saclay University, Institut Gustave Roussy, Villejuif, France., Besse B; Paris-Saclay University, Institut Gustave Roussy, Villejuif, France., Aix SP; Hospital Universitario 12 De Octubre, Madrid, Spain., Callejo A; Hospital Universitari Vall d'Hebron- Vall d'Hebron Institut Oncologia, Barcelona, Spain., Al-Rabi K; King Hussein Cancer Center, Amman, Jordan., Bernabe R; University Hospital Virgen del Rocio, Sevilla, Spain., Greillier L; Aix Marseille University, Assitance Publique-Hôpitaux de Marseille (APHM), Marseille, France., Majem M; Hospital De La Santa Creu I Sant Pau, Barcelona, Spain., Reguart N; Hospital Clinic Universitari de Barcelona, IDIBAPS, Barcelona, Spain., Monnet I; Centre Hospitalier Intercommunal De Creteil, Creteil, France., Cousin S; Institut Bergonie, Bordeaux, France., Garrido P; Hospital Universitario Ramon y Cajal, Madrid, Spain., Robinet G; CHU de Brest, Brest, France., Campelo RG; University Hospital A Coruna-Hospital Teresa Herrera, A Coruna, Spain., Madroszyk A; Institut Paoli-Calmettes, Marseille, France., Mazières J; CHU de Toulouse-Hopital Larrey, Toulouse, France., Curcio H; Centre François Baclesse, CHU Côte de Nacre, Caen, France., Wasąg B; Medical University of Gdansk, Gdansk, Poland., Pretzenbacher Y; EORTC Headquarters, Brussels, Belgium., Grillet F; EORTC Headquarters, Brussels, Belgium., Dingemans AC; Erasmus Medical Center, Rotterdam, the Netherlands., Dziadziuszko R; Medical University of Gdansk, Gdansk, Poland.
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 20; Vol. 42 (12), pp. 1350-1356. Date of Electronic Publication: 2024 Feb 07.
Zobrazit plný text záznamu
7
Akademický článek
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
Autor: Bar J; Sheba Medical Center, Tel Hashomer, Derech Sheba 2, Ramat Gan 5262000, Israel; Tel-Aviv University Medical School, P.O Box 39040, Ramat Aviv, Tel-Aviv 69978, Israel. Electronic address: bar.jair@gmail.com., Esteban E; Central Hospital Universitario Central de Asturias, Avenida de Roma, 33011 Oviedo, Spain., Rodríguez-Abreu D; Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Avenida Marítima del Sur, s/n, 35016 Las Palmas De Gran Canaria, Spain., Aix SP; Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense and CIBERONC, Avenida de Séneca 2, 28040 Madrid, Spain., Szalai Z; Petz Aladár Egyetemi Oktató Kórház, Győr, 9224, Vasvári Pál 2-4, Hungary., Felip E; Vall d'Hebron University, Vall d'Hebron Institute of Oncology (VHIO), Centro Cellex, Carrer de Natzaret, 115-117, 08035 Barcelona, Spain., Gottfried M; Meir Medical Center, 59 Tchernichovsky, Kfar-Sava 4428164, Israel., Provencio M; Hospital Universitario Puerta de Hierro, Calle Joaquin Rodrigo 1, 28222 Madrid, Spain., Robinson A; Queen's University, 90 University Ave, Kingston, Ontario K7L 3N9, Canada., Fülöp A; Országos Korányi Pulmonológiai Intézet, 1121 Korányi Frigyes Út 1, Budapest, Hungary., Rao SB; Ascension Saint Agnes Hospital, 900 S Caton Ave, Baltimore, MD 21229, USA., Camidge DR; University of Colorado School of Medicine, 13001 E 17th Pl, Aurora, CO 80045, USA., Speranza G; Centre Integré de Cancérologie de la Montérégie, Université de Sherbrooke, 3120 boulevard Taschereau, Greenfield Park, Québec J4V 2H1, Canada., Townson SM; Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA., Kobie J; Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA., Ayers M; Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA., Dettman EJ; Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA., Hunkapiller N; GRAIL LLC, 1525 Obrien Dr, Menlo Park, CA 94025, USA., McDaniel R; GRAIL LLC, 1525 Obrien Dr, Menlo Park, CA 94025, USA., Jung B; GRAIL LLC, 1525 Obrien Dr, Menlo Park, CA 94025, USA., Burkhardt D; GRAIL LLC, 1525 Obrien Dr, Menlo Park, CA 94025, USA., Mauntz R; GRAIL LLC, 1525 Obrien Dr, Menlo Park, CA 94025, USA., Csőszi T; Jász-Nagykun-Szolnok County Hospital, 5000 Tószegi út 21, Szolnok, Hungary.
Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Apr; Vol. 190, pp. 107506. Date of Electronic Publication: 2024 Feb 17.
Zobrazit plný text záznamu
8
Akademický článek
Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021).
Autor: Li D; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Loriot Y; Department of Cancer Medicine, Gustave Roussy Institute, INSERM 981, University Paris-Saclay, Villejuif, France., Burgoyne AM; University of California San Diego, San Diego, CA, USA., Cleary JM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Santoro A; IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Rozzano, Italy.; Humanitas University, Pieve Emanuele, Italy., Lin D; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Aix SP; Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense and Ciberonc, Madrid, Spain., Garrido-Laguna I; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Sudhagoni R; Exelixis, Inc., Alameda, CA, USA., Guo X; Exelixis, Inc., Alameda, CA, USA., Andrianova S; Exelixis, Inc., Alameda, CA, USA., Paulson S; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
Publikováno v: EClinicalMedicine [EClinicalMedicine] 2023 Dec 21; Vol. 67, pp. 102376. Date of Electronic Publication: 2023 Dec 21 (Print Publication: 2024).
Zobrazit plný text záznamu
9
Akademický článek
Data-Driven Personalized Care in Lung Cancer: Scoping Review and Clinical Recommendations on Performance Status and Activity Level of Patients With Lung Cancer Using Wearable Devices.
Autor: Aix SP; Hospital Universitario 12 de Octubre, Madrid, Spain., Núñez-Benjumea FJ; Adhera Health, Inc, Santa Cruz, CA.; Innovation & Data Analysis Unit, Virgen Macerana University Hospital, Seville, Spain., Cervera-Torres S; Adhera Health, Inc, Santa Cruz, CA., Flores A; Roche Farma SA, Madrid, Spain., Arnáiz P; Roche Farma SA, Madrid, Spain., Fernández-Luque L; Adhera Health, Inc, Santa Cruz, CA.
Publikováno v: JCO clinical cancer informatics [JCO Clin Cancer Inform] 2023 Sep; Vol. 7, pp. e2300016.
Zobrazit plný text záznamu
10
Akademický článek
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
Autor: Garon EB; David Geffen School of Medicine at University of California Los Angeles/TRIO-US Network, Los Angeles, USA. Electronic address: egaron@mednet.ucla.edu., Reck M; LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany., Nishio K; Department of Medical Oncology, Kindai University, Osaka, Japan., Heymach JV; Department of Thoracic/Head & Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, USA; Department of Cancer Biology, University of Texas, MD Anderson Cancer Center, Houston, USA., Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Novello S; Department of Oncology, AOU San Luigi, University of Turin, Turin, Italy., Paz-Ares L; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain., Popat S; Royal Marsden NHS Trust, London, UK., Aix SP; Hospital Universitario 12 de Octubre, Madrid, Spain., Graham H; Eli Lilly and Company, Indianapolis, USA., Butts BD; Eli Lilly and Company, Indianapolis, USA., Visseren-Grul C; Eli Lilly and Company, Indianapolis, USA., Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
Publikováno v: ESMO open [ESMO Open] 2023 Aug; Vol. 8 (4), pp. 101580. Date of Electronic Publication: 2023 Jun 28.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje